Education
About Us
Working with TipRanks
Follow Us
CERo Therapeutics Holdings (CERO)
OTHER OTC:CERO
Total Valuation
CERo Therapeutics Holdings has a market cap or net worth of $121.14K. The enterprise value is ―.
Market Cap$121.14K
Enterprise Value―
Share Statistics
CERo Therapeutics Holdings has 1,205,402 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,205,402
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
CERo Therapeutics Holdings’s return on equity (ROE) is 4.08 and return on invested capital (ROIC) is 4795.56%.
Return on Equity (ROE)4.08
Return on Assets (ROA)-1.25
Return on Invested Capital (ROIC)4795.56%
Return on Capital Employed (ROCE)12.80
Revenue Per Employee0.00
Profits Per Employee-1.04M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CERo Therapeutics Holdings is ―. CERo Therapeutics Holdings’s PEG ratio is 0.19.
PE Ratio―
PS Ratio0.00
PB Ratio-76.51
Price to Fair Value-76.51
Price to FCF-25.04
Price to Operating Cash Flow>-0.01
PEG Ratio0.19
Income Statement
In the last 12 months, CERo Therapeutics Holdings had revenue of 0.00 and earned -7.73M in profits. Earnings per share was -6.87.
Revenue0.00
Gross Profit-1.16M
Operating Income-15.30M
Pretax Income-7.73M
Net Income-7.73M
EBITDA-6.57M
Earnings Per Share (EPS)-6.87
Cash Flow
In the last 12 months, operating cash flow was -8.67M and capital expenditures -4.00, giving a free cash flow of -6.24M billion.
Operating Cash Flow-8.67M
Free Cash Flow-6.24M
Free Cash Flow per Share-5.18
Dividends & Yields
CERo Therapeutics Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.65
52-Week Price Change-99.98%
50-Day Moving Average3.75
200-Day Moving Average13.32
Relative Strength Index (RSI)14.26
Average Volume (3m)241.38K
Important Dates
CERo Therapeutics Holdings upcoming earnings date is ―, ―.
Last Earnings Date―
Next Earnings Date―
Ex-Dividend Date―
Financial Position
CERo Therapeutics Holdings as a current ratio of 0.50, with Debt / Equity ratio of -70.54%
Current Ratio0.50
Quick Ratio0.50
Debt to Market Cap<0.01
Net Debt to EBITDA0.27
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CERo Therapeutics Holdings has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
CERo Therapeutics Holdings EV to EBITDA ratio is -21.80, with an EV/FCF ratio of -24.73.
EV to Sales0.00
EV to EBITDA-21.80
EV to Free Cash Flow-24.73
EV to Operating Cash Flow-24.73
Balance Sheet
CERo Therapeutics Holdings has $3.80M in cash and marketable securities with $1.15M in debt, giving a net cash position of $2.65M billion.
Cash & Marketable Securities$3.80M
Total Debt$1.15M
Net Cash$2.65M
Net Cash Per Share$2.20
Tangible Book Value Per Share-$1.57
Margins
Gross margin is 1.26%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin1.26%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for CERo Therapeutics Holdings is $0.10, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.10
Price Target Upside-16.67% Downside
Analyst ConsensusHold
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast―